By Barbara Obstoj-Cardwell. Editor
Clinical trial results featured heavily in the news last week, first with Dutch biotech NewAmsterdam releasing data on its hypercholesterolemia candidate obicetrapib. US drug developer MacroGenics announced receipt of a $100 million milestone from Incyte relating to progress in its deal on Zynyz and updated on the development of prostate cancer drug vobra duo. Germany’s BioNTech announced top-line Phase II results of its mRNA cancer immunotherapy BNT111. Also, US pharma major Eli Lilly released new data on its GLP-1 drug tirzepatide – already marketed for diabetes and obesity under the trade names Mounjaro and Zepbound, respectively - in heart failure.
BROOKLYN data solidify obicetrapib’s profile, clean safety ahead of next Phase III's
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze